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Recombinant adeno-associated virus (AAV) vectors 
express ing the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene have been used to deliver CFTR 
to the airway epithelium of cystic fibrosis (CF) patients. 
However, no significant CFTR function has been demon-
strated likely due to low transduction efficiencies of the 
AAV vectors. To improve AAV transduction efficiency for 
human airway epithelium (HAE), we generated a chime-
ric AAV library and performed directed evolution of AAV 
on an in vitro model of human ciliated airway epithelium. 
Two independent and novel AAV variants were identified 
that contained capsid components from AAV-1, AAV-6, 
and/or AAV-9. The transduction efficiencies of the two 
novel AAV variants for human ciliated airway epithelium 
were three times higher than that for AAV-6. The novel 
variants were then used to deliver CFTR to ciliated airway 
epithelium from CF patients. Here we show that our novel 
AAV variants, but not the parental, AAV provide sufficient 
CFTR delivery to correct the chloride ion transport defect 
to ~25% levels measured in non-CF cells. These results 
suggest that directed evolution of AAV on relevant in vitro 
models will enable further improvements in CFTR gene 
transfer efficiency and the development of an efficacious 
and safe gene transfer vector for CF lung disease.
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IntroductIon
Cystic fibrosis (CF) is the most common recessive lethal genetic dis-
order in Caucasian populations resulting from a defect in a single 
gene that encodes the cystic fibrosis transmembrane conductance 
regulator (CFTR), a cyclic adenosine  monophosphate–activated 
chloride ion channel. The pulmonary manifestations of CF account 
for over 90% of the morbidity and mortality.1 In the airway epi-
thelium, mutations in CFTR affect the normal  regulation of ion 
transport, leading to a reduced volume of  airway surface  liquid, 
mucus dehydration, decreased mucus transport, and mucus plug-
ging of the airways. These events result in an inability to prevent 
or eradicate bacterial infections that, over  several decades, lead to 
a progressive decline of lung function.
Restoration of CFTR function to the airway epithelium of CF 
patients is a major goal for alleviating CF lung disease. One thera-
peutic approach has been focused on delivering a normal copy of 
the CFTR gene to the airway epithelium using viral and nonviral-
based gene delivery vectors. Two decades of intense preclinical and 
clinical research have identified diverse vector systems that hold 
promise for CFTR gene delivery to the lung. However, to date, the 
currently available vectors have failed to result in efficacious CFTR 
gene delivery to the ciliated airway epithelium of CF patients.
Adeno-associated virus (AAV)–derived vectors hold consid-
erable promise for CFTR gene delivery due to advances in vector 
production, the relatively stable expression of transgenes and the 
low incidence of inflammation induced by these vectors in vivo. 
AAV-2 vectors carrying the complete human CFTR complemen-
tary DNA (tgAAVCF) have been delivered to the nasal epithelium, 
the sinuses, and lungs of subjects with CF. Although these studies 
indicated that AAV delivery was safe and well tolerated, they did 
not demonstrate expression of functional CFTR or a statistically 
significant improvement in lung function.2 These shortcomings 
likely resulted from a low efficiency of CFTR gene transfer to cells 
that enable corrective CFTR function in the CF airways. The effi-
ciency of CFTR delivery to airway epithelium in vivo using viral 
vectors may be limited by multiple cellular barriers, such as lack of 
relevant receptors in the airway lumen that reduce receptor bind-
ing, internalization, and subcellular processing of vectors. Strategies 
to circumvent these barriers have mainly focused on identification 
and development of different AAV serotypes or by re-engineering 
existing serotypes for improved gene transfer efficiency.3,4
Although AAV-2-based vectors were originally proposed for 
CFTR delivery to CF airways, several groups have now shown 
that other serotypes such as AAV-1, AAV-5, AAV-6, and AAV-9 
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exhibit improved gene transfer efficiency in a variety of  models 
of the lung epithelium.5–9 AAV-1 has been demonstrated to 
be ~100-fold more efficient than AAV-2 and AAV-5 at transduc-
ing human airway epithelial cells in vitro,5 although AAV-1 trans-
duced murine tracheal airway epithelia in vivo with an efficiency 
equal to that of AAV-5.6 Other studies have shown that AAV-5 
is 50-fold more efficient than AAV-2 at gene delivery to human 
airway epithelium (HAE) in vitro and significantly more efficient 
in the mouse lung airway epithelium in vivo.7 AAV-6 has also been 
shown to be more efficient than AAV-2 in human airway epithelial 
cells in vitro and murine airways in vivo.8 The more recent iso-
late, AAV-9, was shown to display greater gene transfer efficiency 
than AAV-5 in murine nasal and alveolar epithelia in vivo with 
gene expression detected for over 9 months suggesting AAV may 
enable long-term gene expression in vivo, a desirable property for 
a CFTR gene delivery vector. Furthermore, it was demonstrated 
that AAV-9 could be readministered to the murine lung with no 
loss of CFTR expression and minimal immune consequences.9
DNA shuffling combined with directed evolution has been pre-
viously used to generate novel AAV vectors that display improved 
transduction efficiency in specific cell types.10,11 Recently, it has 
been demonstrated that directed evolution of the AAV capsid can 
select viral variants with enhanced infection of HAE in vitro.12 
Clearly, the cellular model used for AAV evolution will dictate 
the usefulness of this approach and, therefore, the cellular model 
should represent the appropriate in vivo characteristics of the tar-
get tissue, i.e., the human ciliated airway epithelium. We have now 
applied a directed evolution strategy to select AAV variants that 
exhibit increased transduction efficiency for an in vitro model of 
human ciliated airway epithelium in an attempt to generate more 
efficient gene delivery vectors for CFTR. In our approach, a chi-
meric AAV plasmid library was generated by DNA shuffling a 
series of genes encoding the capsid sequences of eight different 
AAV serotypes (1–9 with the exception of AAV-7).10 Using a plas-
mid library of chimeric AAV capsids we performed directed evo-
lution of AAV on HAE. After five successive rounds of screenings, 
two novel AAV variants were identified with greater transduction 
efficiency for HAE than the parental serotypes AAV-1 and AAV-6. 
We next inserted the shortened CFTR construct (CFTRΔR)13 into 
the two evolved AAV variants and the parental AAV-6 and used 
these vectors to show that our novel variants improved CFTR gene 
transfer efficiency sufficiently to partially restore the CF bioelec-
tric defect characteristic of HAE derived from CF patients (CF 
HAE). Our data demonstrate that directed molecular evolution of 
AAV using DNA-shuffling can be exploited to identify novel viri-
ons with improved efficiency of gene delivery to human ciliated 
airway epithelium and suggest that further development of AAV 
for the treatment of CF lung disease should be explored.
results
directed evolution of AAV variants by dnA shuffling 
and screening on cultures of human ciliated airway 
epithelium
Because traditional AAV-derived vectors transduce human cili-
ated airway epithelium in vitro and in vivo at levels unlikely to 
provide sufficient CFTR delivery for correction of the CF air-
ways phenotype, we sought to generate novel AAV variants with 
improved transduction efficiency for human ciliated airway 
 epithelium by directed evolution on HAE. We cycled our AAV 
capsid library as previously described10 in HAE using co-infection 
with wild-type adenovirus (AdV, dl309) to amplify infectious AAV 
variants (Figure 1a)14 Because HAE are relatively resistant to AdV 
infection after lumenal inoculation of HAE unless epithelial tight 
junctions are disrupted to reveal basolateral AdV receptors,15,16 the 
apical surfaces of HAE were first exposed to sodium caprate to 
transiently open tight junctions immediately before AdV inocu-
lation.17 A schematic representation of our strategy is shown in 
Figure 1a. After five cycles of screening on HAE derived from dif-
ferent donors, DNA extracted from cell lysates obtained after the 
fifth cycle served as a template for PCR and was cloned into the 
AAV helper plasmid pXR. Ten individual clones were picked and 
subjected to sequence analysis. Two chimeric AAV variants were 
present in the population: a chimera of AAV-1 and AAV-6 capsids 
and a chimera of AAV-1, AAV-6, and AAV-9 capsids. These chime-
ras are referred to as HAE-1 and HAE-2, respectively and are rep-
resented schematically in Figure 1b. HAE-1, a chimera of AAV-1 
and AAV-6 with only amino acid residues 583–641 derived from 
AAV-6, results in only two amino acid changes, F584L and A598V 
compared to the parent AAV-1. For HAE-2, the chimera was more 
complex, with amino acid residues 1–30, 105–193 derived from 
AAV-9 and, amino acid residues 31–104, 194–641 from AAV-6. 
The carboxyl-terminal amino acid residues 642–737 represented 
those of AAV-1 (Figure 1b).
Amino acid differences between the chimeric HAe-1 
and HAe-2 and their parental viruses are localized 
around the icosahedral threefold axes
Three-dimensional models were generated for the chimeric 
HAE-1 and HAE-2 viruses and compared to the structures of 
the parental AAV-1 and AAV-6 viruses with respect to the role 
of capsid amino acid contributions to their enhanced transduc-
tion phenotypes. Mapping of the amino acid contributions from 
the parental AAV-1 and AAV-6 viruses onto a surface contour 
representation of these models showed a difference in paren-
tal origin of the five amino acids which differ between AAV-1/
AAV-6, all located either on the interior or exterior capsid surface 
of these new viruses (Figure 1c). Of the five amino acid differ-
ences, AAV-1 contributes one outer surface residue (E531) and 
two inner surface residues (E418 and N642) to HAE-1 and AAV-6 
contributes two outer surface residues (L584 and A598). For chi-
meric HAE-2, all outer capsid surface localized amino acid differ-
ences between AAV-1 and AAV-6 are contributed from AAV-6 
(K531, L584, and V598). The two inner capsid surface amino acid 
differences are contributed from both AAV-1 (N642) and AAV-6 
(D418). The contribution of the AAV-9 amino acids to the chime-
ric HAE-2 virus could not be modeled because these are located 
on the N-terminal region of the AAV viral protein (VP) that is 
disordered in all the structures that have been determined to date 
by X-ray crystallography and cryo-electron microscopy.
enhanced transduction of human ciliated airway 
epithelium by novel AAV variants
We determined the transduction efficiency of the chimeric AAV 
variants, HAE-1 and HAE-2, on our in vitro model of HAE by 
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packaging all recombinant AAV vectors with double-stranded 
green fluorescent protein (GFP) or luciferase expression cas-
settes. Both novel AAV capsids were competent in packaging 
recombinant AAV vectors to titers similar to the parental sero-
type AAV-1/AAV-6. To assess the numbers of cells transduced 
after inoculation of the apical surface of HAE with equal titers 
of chimeric capsids HAE-1, HAE-2, or the parental serotypes, 
AAV-1, AAV-5, AAV-6, and AAV-9 (multiplicity of infection 
(MOI) ~105), we monitored GFP transgene expression en face 
over time. The number of GFP-positive cells was found to be 
maximal at 1 week postinoculation (p.i.) and representative epi-
fluorescence images are shown in Figure 2a. These data show that 
the parental serotypes, AAV-1, AAV-5, and AAV-9, transduced 
HAE poorly although AAV-6 transduction was repeatedly the 
best of the parental strains. Both chimeric capsids HAE-1 and 
HAE-2 transduced significantly more cells than either AAV-1, 
AAV-5, AAV-6, or AAV-9, with HAE-2 transduction being the 
most efficient of the two variants. Thus, based on this assay, we 
find that our directed evolution variants HAE-1 and HAE-2 are 
the most efficient vectors in HAE cells, outperforming all other 
AAV serotypes tested in parallel (AAV-1, AAV-5, AAV-6, and 
AAV-9).
Although monitoring GFP-positive cells in real-time 
enabled quantitation of the numbers of cells transduced, to fur-
ther assess improvements in gene transfer efficiency with our 
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Figure 1 selection of novel AAV variants tropic to human ciliated airway epithelium in vitro. (a) The strategy for enrichment of HAE tropic AAV 
variants by repetitive screenings of combinatorial AAV shuffling library on HAE (see Materials and Methods for details). A DNA-shuffling AAV library was 
inoculated onto the apical surface of HAE, followed by sodium caprate treatment/wild-type adenovirus infection at 24 hours, and cell lysis at 5 days 
to recover selected AAV viruses. The harvested AAV pool was then used for subsequent screening, and the process was repeated four more times. The 
recovered AAV viruses at the end of screenings were subjected to sequencing analysis. (b) Primary structures of two dominant AAV variants selected 
from successive screening on HAE, named as chimeric HAE-1, chimeric HAE-2, respectively. Sequence analysis and alignment with parental serotype 
sequences revealed the chimeric capsid subunit (VP1) are derived from AAV-1, AAV-6, and AAV-9. (c) Surface contour representations of the VP3 three-
dimensional models of the HAE chimeric viruses. The front and back views of a trimer are shown for HAE-1 (top left and right) and HAE-2 (bottom left 
and right) which the surface colored according to the sequence contribution from the parental virus (red for AAV-1, blue for AAV-6) as depicted in b. 
The five amino acids that differ between AAV-1 and AAV-6 in the modeled region are colored black if contributed from AAV-1 or yellow if contributed 
from AAV-6 and are labeled. These images were generated in the program PyMol. AAV, adeno-associated virus; HAE, human airway epithelium.
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expressing a luciferase transgene. Luciferase enzyme activity in 
HAE was assessed 2 weeks p.i. with our novel AAV variants and 
the two best parent vectors (AAV-1 and AAV-6) (MOI ~103) 
(Figure 2b). Consistent with the findings for GFP-expressing 
vectors, AAV-6 expressed more luciferase activity in HAE than 
AAV-1, whereas the AAV variants, HAE-1 and HAE-2, pro-
duced two- to threefold more luciferase activity than AAV-1 and 
AAV-6, likely due to the increased numbers of cells targeted by 
these novel variants. Virus binding assay (see Supplementary 
Figure S1) supports a step downstream of initial binding as 
likely enhancement for these chimeric capsid transduction on 
HAE cells. Thus, two novel AAV variants have been generated 
by our molecular evolution strategy that have improved trans-
duction efficiency for HAE compared to the parental AAV sero-
types, AAV-1, AAV-6, and AAV-9. In  addition, the two novel 
variants have improved transduction efficiencies over AAV-5 
that has been previously reported to  efficiently transduce HAE 
cells in vitro.7
transduction efficiency of chimeric capsids HAe-1 
and HAe-2 in human ciliated airway epithelia can be 
enhanced using pharmacological methods
It has been previously shown that AAV transduction of HAE 
can be enhanced by coadministration at the time of inoculation 
with proteasome-modulating agents, such as tripeptidyl alde-
hyde [N-acetyl-l-leucinyl-l-leucinyl-l-norleucinal (LLnL)], 
and chemotherapeutic agents, such as doxorubicin (Dox).18,19 
To test whether these agents improved the transduction effi-
ciency of chimeric capsids HAE-1 and HAE-2 in HAE cells, 
the proteosome inhibitor LLnL (40 μmol/l) and/or the DNA 
disrupting agent Dox (5 μmol/l) were co-inoculated onto the 
apical surfaces of HAE with AAV-6, chimeric capsids HAE-1, 
and HAE-2 expressing GFP. These agents (and AAV) were main-
tained on the apical surface of HAE for a further 10 hours before 
removal. GFP transgene expression assessed over time indicated 
that the maximal numbers of transduced cells was reached at 
1 week p.i. In the absence of pharmacological reagents, the per-
centage of GFP-positive cells was greater for chimeric capsids 
HAE-1 and HAE-2 compared to AAV-6 confirming our earlier 
data (Figure 3a,b). For all vectors, both the numbers of AAV 
transduced cells and the intensity of GFP fluorescence increased 
after co-incubation with LLnL or Dox or both drugs together 
(Figure 3a,b). Both LLnL and Dox increased AAV transduction 
independently with the highest level of transduction efficiency 
produced by co-incubation of AAV with both drugs in combina-
tion. These data are consistent with previous reports that pro-
teasome inhibitors LLnL and Dox can be additive.19 The highest 
transduction efficiencies were obtained with chimeric capsids 
HAE-1 or HAE-2 when coadministered with both LLnL and 
Dox with 6–7% of the surface epithelial cells being transduced 
(Figure 3b). Under these conditions, HAE-1 and HAE-2 vectors 
provided a twofold increase in transduction efficiency compared 
to AAV-6 when coadministered with LLnL and Dox. Because 
it has been reported that AAV transduction efficiency in HAE 
increased after disruption of epithelial cell tight junctions,20 
we determined whether the addition of these reagents affected 
tight junction permeability at the time of AAV inoculation. 
Transepithelial resistance was measured immediately after inoc-
ulation of chimeric HAE-2 in the absence and presence of LLnL 
and Dox. Figure 3c shows that neither AAV vector nor LLnL/
Dox affected transepithelial resistance indicating that enhance-
ment of AAV-mediated transduction did not occur by exposing 
basolateral membranes to vectors. These results suggest a down-
stream step to virus binding is influenced by chimeric capsid 
(e.g., endosome escape, nuclear entry, etc.). To identify the cell 
types targeted by AAV vectors +/− LLnL/Dox, we used a ciliated 
cell-specific immunomarker (β-tubulin IV antibody) and deter-
mined colocalization of immunofluorescence with that of GFP 
by optical XZ confocal microscopy. These analyses revealed that 
AAV-6, HAE-1, and HAE-2 vectors only transduced columnar, 
lumen-facing epithelial cells and that both ciliated and noncili-
ated cells were transduced (Figure 3d). Although the numbers 
of cells transduced were variable dependent on the AAV vector 
used the cellular tropism was not obviously different for vari-

























Figure 2 Improved transduction efficiencies by the novel AAV variants. (a) HAE were inoculated with equal titers (MOI = 100,000) of AAV-1, 
AAV-5, AAV-6, AAV-9, HAE-1, and HAE-2, all of which contain a double strand GFP reporter gene. Representative en face fluorescence photomicro-
graphs showing GFP-positive cells in HAE cells were obtained at 14 days postinoculation. (b) Quantitative comparisons of transduction efficiency 
using luciferase expressing vectors. HAE were inoculated with luciferase expressing AAV vectors (MOI = 1,000), cell lysates were harvested at 
2 weeks postinoculation, and luciferase activities measured. *P < 0.01. AAV, adeno-associated virus; GFP, green fluorescent protein; MOI,  multiplicity 
of infection.
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Packaging of cFtr into AAV and determination 
of expression efficiencies
To test whether chimeric capsids HAE-1 or HAE-2 were capable 
of delivering CFTR to sufficient cells to provide correction of 
the CF bioelectric Cl− defect we engineered our novel variants 
to express CFTR. However, the open reading frame size of full-
length CFTR (4.2 kb) poses a significant challenge for producing 
AAV-CFTR vectors as additions of regulatory elements includ-
ing promoter/enhancer and poly-adenylation (poly-A) sequences 
would exceed the normal packaging capacity of AAV (~5 kb). 
We have attempted to circumvent this problem by testing three 
different CFTR constructs to enable efficient packaging of AAV-
CFTR. These constructs are shown schematically in Figure 4a. 
AAV-CFTR-1 contains a full-length cytomegalovirus promoter 
(CMV), full-length CFTR, and a poly-A sequence. With these ele-
ments the genome size (5.7 kb) exceeds the typical 5 kb packaging 
capacity of AAV. AAV-CFTR-2 contains full-length CFTR and a 
poly-A sequence with no exogenous promoter producing a 5.1-kb 
genome with CFTR expression driven by the AAV terminal repeat 
sequence. AAV-CFTR-3 contains a shortened CMV promoter, an 
R-domain-deleted CFTR and shortened poly-A tail, with a total 
genomic size of 4.9 kb. To verify whether these constructs could 
be packaged by AAV vectors, we generated viruses in 293T cells 
using AAV-6 capsids and quantitated viral particles by dot-blot. 
Viral DNA isolated from equal numbers of viral particles (genome 
copy number tittered by dot-blot) was analyzed by Southern blot 
to determine the genomic sizes and genome integrity. Compared 
to a 5 kb plasmid marker (Figure 4b, lane 1), AAV-CFTR-1 pro-
duced a smear with no discrete band at 5.7 kb (Figure 4b, lane 
2), suggesting either inefficient packaging or truncated fragments 
were incorporated by the capsid. AAV-CFTR-2 and AAV-CFTR-3, 
however, each displayed one discrete band at their respective pre-
dicted sizes (Figure 4b, lanes 3 and 4) indicating efficient packag-
ing of these smaller constructs.
To determine the relative transcriptional activities of the 
different constructs in directing CFTR expression, 293T/HeLa 
cells were transfected with these three plasmid constructs, and 
CFTR present in cell lysates analyzed by western blot. Using 
human Calu-3 cell lysate as a positive control for human fully 
glycosylated CFTR (Figures 4c,d, lane 1), transfection of 293T 
cells with the genomes of AAV-CFTR-1 (Figure 4c, lane 3) 
and AAV-CFTR-3 (Figure 4d, lane 3) resulted in robust CFTR 
expression suggesting the shortened CMV/poly-A sequences 
achieve a high level of CFTR expression. On the contrary, no 
CFTR expression was observed from cells transfected with 
AAV-CFTR-2 genomes (Figure 4c, lane 4), indicating the atypi-
cal AAV terminal repeat promoter in AAV-CFTR-2 has a much 
lower transcriptional activity than CFTR-1 or CFTR-3. In sum-
mary, AAV-CFTR-1 was found to be too large to be efficiently 
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Figure 3 effects of pharmacological modulation on AAV transduction of HAe. HAE cultures were inoculated apically with AAV variants expressing 
GFP (MOI = 10,000), in the presence or absence of the proteasome inhibitor, LLnL (40 μmol/l), and/or the anthracycline, Dox (5 μmol/l), as outlined 
in Materials and Methods. (a) At 2 weeks postinoculation, en face epifluorescence images of GFP expression were obtained, with representative 
images. (b) The relative abundance of GFP-positive cells was quantitated and compared. (c) After inoculation of HAE-2 in the absence and presence 
of LLnL and Dox, TER was measured. (d) Optical x-z confocal fluorescent images showed both ciliated and nonciliated columnar epithelial cells were 
transduced by AAV. Cilia were immunolabeled red as described in Materials and Methods. *P < 0.05. AAV, adeno-associated virus; Dox, doxorubicin; 
GFP, green fluorescent protein; LLnL, N-acetyl-l-leucinyl-l-leucinyl-l-norleucinal; TER, transepithelial resistance.
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amounts of CFTR. Therefore, only AAV-CFTR-3 was used in 
subsequent experiments.
expression of cFtrΔr in human cF ciliated  
airway epithelial cells
To test the efficiency of AAV-mediated CFTR expression in 
cells, AAV-CFTR-3 was packaged by capsids of AAV-6, HAE-1 
and HAE-2 variants, and inoculated on to HeLa cells and HAE 
derived from CF patients (CF HAE), with co-inoculation with 
wild-type AdV (MOI = 5). CFTR expression in HeLa and CF 
HAE was analyzed by western blot at 2 and 5 days p.i., respectively. 
For HeLa cells (Figure 4d), AAV6-CFTR-3 expressed the largest 
amount of CFTR protein (Figure 4d, lane 5) when compared to 
that expressed by chimeric HAE-1 (Figure 4d, lane 6) and HAE-2 
(Figure 4d, lane 7). However, for CF HAE cells (Figure 4e), chi-
meric HAE-1-CFTR-3 (Figure 4e, lane 4) and HAE-2-CFTR-3 
(Figure 4e, lane 5) showed a greater level of CFTR expression 
compared to AAV1-CFTR3 (Figure 4e, lane 2) and AAV6-CFTR3 
(Figure 4e, lane 3). These data suggest that the novel AAV variants 
are adapted for transduction and replication in HAE cells unlike 
the parental AAV that transduce HeLa cells more efficiently.
novel AAV variants deliver cFtrΔr to cF HAe 
and partially correct the cF bioelectric chloride 
ion transport defect
To test whether AAV capsid variants were capable of restoring suf-
ficient CFTR function to CF HAE to generate cyclic adenosine 
monophosphate–activated chloride ion transport, CF HAE cells 
were inoculated with AAV-CFTR-3 packaged by AAV-6, variants 
HAE-1, HAE-2 capsids. Vectors were inoculated onto CF HAE 
cells at an MOI of 4 × 105 in the presence of LLnL and Dox as 
described earlier. Non-CF HAE and CF HAE cells inoculated with 
AAV6-GFP or mock-inoculated with vector vehicle alone were 
included as controls and assays performed 2 weeks p.i.
First, we determined by quantitative reverse transcription–PCR 
the relative expression levels of CFTR mRNA in CF HAE cells that 
was produced by AAV vectors compared to endogenous CFTR 
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Figure 4 Analysis of cFtr expressing constructs. (a) The three CFTR expressing constructs that were tested. Construct #1 (AAV-CFTR-1) contains a 
CMV promoter, a full-length CFTR open reading frame, and a poly-adenylation signal. Construct #2 (AAV-CFTR-2) contains no exogenous promoter 
sequence with CFTR expression driven by AAV ITR. Construct #3 (AAV-CFTR-3) contains a truncated minimal CMV promoter, an R-domain-deleted 
CFTR, and a truncated poly-A signal. The length of each construct is indicated. TR, terminal repeats; CMV, CMV promoter; CFTR, cystic fibrosis trans-
membrane conductance regulator; PA, poly-adenylation signal sequence; mCMV, minimal CMV promoter; CFTRΔR, R-domain-deleted CFTR; mPA, 
minimal poly-A sequence. (b) Packaging efficiency is dependent on vector size. Vector DNA isolated directly from AAV virions was run on an alkaline 
agarose gel, followed by Southern-blot analysis probed with CFTR-specific fragment. The AAV-CFTR vector fragment was a control plasmid of known 
size (5.0 kb) (lane 1), AAV-CFTR-1 (lane 2), AAV-CFTR-2 (lane 3), and AAV-CFTR-3 (lane 4). (c). Western-blot analysis of CFTR transgene expression 
in 293T cells transfected with AAV-CFTR plasmids. 293T cells were transfected with constructs #1 and #2 at 3 μg/10-cm plate, and cell lysates were 
prepared at 48 hours postinoculation, and subjected to western-blot analysis for CFTR expression. Calu-3 cells were used as positive control (lane 1). 
Lane 2 was mock transduced. Lanes 3 and 4 were from AAV-CFTR-1 and AAV-CFTR-2, respectively. Arrow indicates the fully glycosylated mature 
form of CFTR. (d). Western-blot analyses CFTR transgene expression in HeLa cell 48 hours postinoculation. HeLa cells were infected with different 
AAV serotypes packaged with AAV-CFTR-3 at MOI of 10,000 and co-infected with dl309 (MOI of 5). Positive control (lane 1), mock infection control 
(lane 2), transfection of plasmid AAV-CFTR-3 (lane 3), lanes 4–7 are infected from AAV-1, AAV-6, HAE-1, HAE-2. (e) CF HAE were inoculated with 
AAV-CFTR-3 vectors packaged with different capsids (MOI = 10,000), super-infected with wild-type adenovirus (MOI = 5) following caprate treat-
ment 24 hours after infection, and at 1 week after AAV inoculations, analyzed for CFTR expression by western blot. Lane 1, mock; 2, AAV-1; 3, AAV-6; 
4, HAE-1; 5, HAE-2, respectively. AAV, adeno-associated virus; CFTR, cystic fibrosis transmembrane conductance regulator; CMV, cytomegalovirus; 
MOI, multiplicity of infection.
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or AAV6-GFP, produced significantly increased levels of CFTR 
mRNA over endogenous CFTR mRNA levels (Figure 5a). Variant 
HAE-1 and HAE-2 likely expressed CFTR mRNA at greater levels 
than AAV6-CFTR because more cells were transduced by these 
chimeric capsids confirming our earlier transduction efficiency 
data (Figure 2).
Next, we performed Ussing chamber studies to determine 
the presence of functional CFTR ion channel activity by maxi-
mally activating CFTR with forskolin (a cell permeable activa-
tor of adenylate cyclase to increase intracellular cyclic adenosine 
monophosphate). Significantly increased forskolin-inducible 
short-circuit currents (Isc) were observed in CF HAE cells inocu-
lated with chimeric capsids HAE-1 (2.95 ± 0.82 μA/cm2, n = 5, 
P < 0.01) and HAE-2 (3.92 ± 2.0 μA/cm2, n = 5, P < 0.01) when 
compared to those in CF HAE cells inoculated with AAV6-
CFTR, AAV6-GFP, or mock-inoculated controls. Representative 
traces and calculated mean changes in forskolin-mediated 
short-circuit currents are shown in Figure 5b,c. No significant 
differences in forskolin-induced Isc between AAV6-CFTR and 
AAV6-GFP or mock inoculations were observed. By compari-
son to forskolin-mediated CFTR activation in non-CF HAE cells 
performed in parallel, we conclude that chimeric HAE-1 and 
HAE-2 expressed sufficient CFTR in enough cells to restore 25 
and 31% of the normal CFTR response to forskolin, respectively. 
These data demonstrate that the novel AAV variants partially 
restore the CFTR bioelectric defect that is a characteristic of the 
CF airway epithelia phenotype. As the most likely reason that 
these novel variants restore 20–30% CFTR-mediated ion trans-
port to that of normal levels was the relatively low numbers of 
cells (~6%) transduced by chimeric HAE-1 and HAE-2 capsids, 
it is not clear if continued further evolution of these vectors for 
increased transduction efficiency in HAE will likely improve the 
ability to correct the bioelectric defect in CF HAE cells. Although 
further development and evolution of AAV-based vectors holds 
significant promise for the potential use of AAV-derived vec-
tors as a therapeutic strategy to reverse CF lung disease, success 
may require additional steps to remove physical barriers (mucus 
layer, etc.) in order to reach full potential.
dIscussIon
AAV vectors remain promising candidates for gene therapy appli-
cations, due to low pathogenicity, broad tissue and cell  tropism, 
lack of cellular immune responses, and the ability to mediate 
long-term gene expression. However, to date, some cell types 
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Figure 5 novel AAV variants mediate CFTR gene delivery to cF HAe and partially restore forskolin-sensitive chloride ion transport. CF HAE 
were inoculated with AAV-CFTR-3 vectors packaged with the capsids indicated at MOI of 4 × 105 vector genomes/cell in the presence of LLnL and Dox 
(see Materials and Methods for details). (a) CFTR mRNA levels in CF HAE 14 days after inoculation with AAVGFP or AAV-CFTR and relative to mRNA 
levels in mock-transduced CF HAE (n = 2). (b) Representative traces of transepithelial PD measurements (PD spikes in response to a current pulse for 
resistance calculation were removed) performed in Ussing chambers at 14 days postinoculation showing responses to sequentially added amiloride 
(Amil), forskolin (Fskl), and CFTR172. A representative PD response by a non-CF HAE is shown for comparison. A small Fskl response was seen in CF 
HAE inoculated with AAVGFP or mock consistent with the residual activity of CFTR 621 + 1G (T allele). (c) Summary data for Fskl-activated changes in 
calculated short-circuit current (ΔIsc) in CF HAE at 14 days postinoculation (mean (SD)). Fskl responses for non-CF HAE were included for comparison. 
*P < 0.01. AAV, adeno-associated virus; CFTR, cystic fibrosis transmembrane conductance regulator; LLnL, N-acetyl-l-leucinyl-l-leucinyl-l-norleucinal; 
PD, potential difference.
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As CF lung disease is due to the genetic absence of  functional 
CFTR in the airway epithelium, this tissue is a major target 
for AAV-based vector gene delivery strategies. Until recently, 
attempts using commonly available AAV vectors for gene deliv-
ery to human ciliated airway epithelium in vitro and in vivo have 
resulted in little or no evidence that efficacious CFTR delivery was 
obtained, a result attributed to the low transduction efficiency of 
the commonly available AAV vector serotypes.
One strategy to increase the transduction efficiency of AAV 
vectors is to identify new AAV variants with improved trans-
duction efficiencies for ciliated airway epithelium. In addition 
to  naturally evolved AAV isolates, several strategies to develop 
hybrid AAV serotype vectors have been formulated in recent 
years. The generation of mosaic or chimeric vectors through 
rational design,21 transcapsidation,22 and marker-rescue/domain-
swapping approaches,23 respectively, have advanced progress in 
this regard. More recently, combinatorial strategies for engineer-
ing AAV vectors using error-prone PCR, DNA shuffling, and other 
molecular cloning techniques have been established.10–12,24–26 The 
latter library-based approaches can serve as powerful tools in the 
generation of novel AAV capsids with altered retargeted tropism, 
immunogenicity, and improved efficacy as gene delivery vectors.
In this study, we subjected a chimeric AAV capsid library, 
generated by DNA-shuffling serotypes 1–9 (excluding serotype 7), 
to five cycles of screening after inoculation of the apical surface 
of an in vitro model of HAE. Using these methods, we identi-
fied two novel chimeric AAV isolates, HAE-1 and HAE-2, with 
improved transduction efficiency, from which the majority of 
their capsid sequences were derived from serotypes AAV-1 and 
AAV-6 (Figure 1b). Clear differences in transduction efficiency 
are observed in HAE between AAV-1, AAV-5, AAV-6, and AAV-9 
when compared to the chimeric HAE viruses with a rank order of 
efficiency as follows: AAV-1/AAV-5/AAV-9 < AAV-6 < HAE-1 < 
HAE-2. The improved transduction in HAE observed for AAV-6 
compared to AAV-1 and that of chimeric HAE-1 compared 
to AAV-6 suggests that some of the six amino acids that differ 
between AAV-1 and AAV-6 confer an advantage to AAV-6. We 
have initiated efforts to map critical residues using both AAV-1 
and AAV-6 single amino acid exchanged these residues between 
capsid backbone as previously described in our lab. For HAE-2 
which showed the best overall transduction efficiency in HAE, all 
the surface amino acids are derived from AAV-6 with an interior 
residue at 418 also from AAV-6. These observations suggest that 
the different AAV-1 and AAV-6 variable amino acids combine to 
confer improved infection of the chimeric viruses for HAE. Such 
molecular events could improve cell binding, internalization, 
and/or trafficking of the novel variants. Mutation of these vari-
able amino acids in the parental viruses and the characterization 
of the mutant viruses by biochemical and cell-based assays, such 
as ability of the viruses to bind to cells, is expected to provide fur-
ther insight into the mechanism(s) underlying the increased air-
way epithelial cell transduction of these AAV variants. As a first 
step toward this analysis, we performed binding assays with our 
parental and variant AAVs on HAE that showed no significant 
differences in the ability of these vectors to bind to the apical sur-
faces of HAE (see Supplementary Figure S1). Given these data, 
we predict that increased transduction efficiencies observed with 
our novel variants are likely due to alteration of events that occur 
post-attachment of AAV to the airway epithelial cells.
The initiating cause of CF lung disease is the dysfunction 
of mutant CFTR in epithelial cells that line the human airways. 
Although it is not established which cell types or airway regions 
(i.e., airway surface epithelium versus submucosal gland epithe-
lium) will require correction of CFTR function, the accessibility of 
the surface airway epithelium to intralumenally delivered vectors 
and the presence of CFTR in epithelial cells that line the surface of 
the conducting airways suggest that targeting CFTR delivery to the 
airway surface epithelium will provide therapeutic benefit to CF 
patients. Reintroduction of CFTR to airway epithelial cells using 
gene delivery vectors remains a rational strategy toward develop-
ing a treatment for this disease. However, preclinical studies and 
clinical trials in CF patients using viral and nonviral vector systems 
have demonstrated negligible efficacy of CFTR delivery. Previously, 
it was shown that delivery of CFTR to as few as 6–10% of human 
CF airway epithelial cells in vitro could restore normal levels of 
chloride ion transport to levels of that measured in non-CF cells. 
However, these experiments performed in homo genous epithelial 
cell types that over expressed CFTR using a retroviral-based vec-
tor were polarized but undifferentiated thus did not represent the 
morphological characteristics of the human ciliated airway epi-
thelium in vivo.27 More recently, using a novel, recombinant virus 
vector that targets ciliated cells it has been shown that restoration 
of airway surface liquid volume and mucus transport to CF HAE 
requires CFTR expression in ~25% of surface epithelial cells.28 In 
particular, this study also demonstrated that if CFTR expression 
in individual cells exceeded endogenous levels of CFTR expres-
sion, then the ability to restore fluid and mucus transport to CF 
HAE was directly related to the numbers of cells expressing CFTR. 
In this report, we demonstrate that ~3% of surface epithelial cells 
are transduced after apical inoculation of CF HAE with our novel 
AAV variants (Figure 3a,b). Coadministration of LLnL and Dox, 
further increased this transduction efficiency to ~6–7%, although 
the augmentation of our novel AAV variants by these reagents 
were much less than reported previously for AAV-2 and AAV-5.5 
We assume that the transduction ability of these novel serotypes 
in HAE differs from that of AAV-2 and AAV-5 by virtue of altered 
subcellular trafficking profiles or distinct ubiquitin/ proteasome 
sensitivities. Therefore, our novel AAV variants although greatly 
improved over the parental AAV serotypes, still fall short of the 
transduction efficiencies likely required restoring fluid and mucus 
transport to CF HAE. Further evolution of AAV vectors for 
increased transduction efficiency in HAE may enable efficacious 
transduction efficiencies to be obtained.
In addition to identifying novel AAV capsid variants that 
exhibit improved HAE transduction, in this report we have 
applied a strategy to overcome the small packaging capacity of 
AAV. Due to the relatively large size of full-length CFTR, addition 
of a CMV promoter and a poly-A sequence exceeds the standard 
AAV packaging capacity (~5 kb) (Figure 4a), resulting in a five to 
tenfold decrease in viral titer (data not shown) and the packag-
ing of transgene fragments under 5 kb (Figure 4b). As mentioned 
earlier,  several approaches have been reported to overcome the 
packaging limitations of AAV, including the use of split genome 
systems,29,30 the construction of CFTR minigenes,13,31,32 the use of 
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minimal promoter elements,33 and the use AAV vectors to deliver 
targeted trans-splicing signals to repair the endogenous CFTR 
mRNA.34 In this study, we tested several options that were avail-
able to us to generate a useful construct, AAV-CFTR-3, which 
contained a shortened CMV promoter (173 bp), an R-domain-
deleted CFTR and 49 bp poly-A tail, flanked by TR2 with a total 
size of 4.9 kb. We determined this construct could be packaged by 
AAV with no impact on vector production (data not shown) or 
infectivity (Figure 4d,e).
Several groups are developing AAV vectors for CF gene trans-
fer purposes and contradictory data exist as to which AAV sero-
type is most efficient at transducing HAE. Previously, it has been 
shown that AAV-5 expressing a CFTR minigene was able to fully 
correct the chloride ion transport defect in CF epithelial cells.13 
In our hands, we would predict based on comparison of AAV-5 
and AAV-6 transduction efficiency in HAE that AAV-5 would 
not target sufficient numbers of epithelial cells in our model of 
human CF ciliated airway epithelium to display any significant 
correction of the CF bioelectric defect. More recently, a novel 
AAV serotype generated by directed evolution by methods similar 
to those described here was shown to fully correct the CF bio-
electric defect to non-CF levels.12 Another previous report indi-
cated that AAV-2 vectors expressing a similar CFTR construct 
and coadministered with pharmacological reagents as we used 
here dramatically enhanced CFTR gene delivery and the ability to 
correct CFTR-mediated ion transport.35 In our hands, using our 
model of human ciliated airway epithelium, AAV-1 and AAV-6 
were consistently more efficient (>100 times) than AAV-25 or 
AAV-5 after apical inoculation. The discrepancies between these 
studies with AAV serotypes from different laboratories may be 
due to several variables such as the vector purification methods, 
the MOI used and/or the differentiation state of the HAE models 
used for screening/transduction studies. We note that one differ-
ence between our studies and those of others is that AAV library 
selection and transduction studies were performed on human air-
way cultures 2 weeks after cell seeding, whereas we routinely used 
cultures 4–6 weeks after seeding.12 In our hands, this extended cell 
culture time is required for full differentiation of airway epithelial 
cells into ciliated/nonciliated cells. After only 2 weeks of culture, 
our model of epithelial cells represents a polarized, but not fully 
differentiated, airway epithelium (see Supplementary Figure S2). 
To test whether transduction efficiency of AAV would be affected 
by the time of culture of our airway model, we inoculated the api-
cal surfaces of cultures derived from the same patient grown for 
2 or 4 weeks with equal amounts of AAV6-GFP and monitored 
GFP-positive cells over time. Transduction efficiency in 2-week 
old cultures was significantly better than for 4-week old cultures 
(see Supplementary Figure S3), suggesting an increased ability of 
AAV vectors to transduce younger, less differentiated airway epi-
thelial cells. Although differences in culture techniques between 
laboratories may also account for the differences in transduction 
efficiencies of AAV variants, further testing of genetically identi-
cal AAV vectors on fully differentiated cells derived from single 
patient sources will be required to resolve some of these differ-
ences. It should be noted that full correction of in vitro HAE may 
not be a complete predictor of human lung but is the gold  standard 
at the moment.
In conclusion, our data presented here provides evidence that 
novel AAV variants generated through directed evolution on a spe-
cific target tissue, i.e., human ciliated airway epithelium are capable 
of transducing the target tissue more efficiently than the parental 
serotypes included in the library. When these novel AAV variants 
expressing CFTR are coadministered with proteasome inhibitors 
and anthracycline compounds, they are capable of partially cor-
recting the bioelectric defect of CF HAE. It remains to be deter-
mined whether this partial level of correction would be beneficial 
to CF airway disease. Thus, we suggest that directed in vitro evolu-
tion of AAV through screening a DNA-shuffled virus library on 
relevant target cells is useful in generating novel AAV variants with 
improved tropism. The two novel AAV variants HAE-1 and HAE-2 
identified in this study warrant further studies in vitro and in vivo.
MAterIAls And MetHods
Cell lines and viruses. 293T cells and HeLa cells were maintained in 
Dulbecco’s modified Eagle’s medium (Sigma, St Louis, MO) supplemented 
with 10% fetal bovine serum and penicillin–streptomycin (100 U/ml) with 
5% CO2 at 37 °C. Wild-type AdV dl309 has been described previously.
14
AAV production and titration. Recombinant AAV vectors containing 
GFP, luciferase, or CFTR, were produced using the triple plasmid transfec-
tion protocol as described and virus titers were determined by dot-blot 
analysis.36
Generation of ciliated HAE in vitro. Fresh human tracheobronchial epi-
thelial cells were isolated from excess surgical specimens resected at lung 
transplantation by the University of North Carolina Cystic Fibrosis Center 
Tissue Culture Core under University of North Carolina institutional 
review board–approved protocols. Briefly, primary cells derived from sin-
gle patient sources were expanded on plastic to generate passage 1 cells, 
which were plated at a density of 250,000 cells/cm2 on permeable mem-
brane support (Transwell-Col, 12 or 24-mm diameter, Corning; Millicells, 
12-mm diameter, Millipore, Corning, NY), and maintained in a specialty 
media.37 Differentiation was induced under air–liquid interface; and the 
cultures were considered “matured” (in ~4–8 weeks) when significantly 
ciliated (>50% ciliated cells). Only fully differentiated ciliated cultures were 
used in all experiments.
HAE-1 and HAE-2 model building. To enable three-dimensional visual-
ization of the amino acid differences between the HAE chimeric viruses 
and the parental AAV-1 and AAV-6, a homologous VP3 structural model 
(residues 217–736, VP1 numbering) was first generated for AAV-6 based 
on the crystal structure of AAV-1 VP3 monomer (L. Govindasamy and 
M. Agbandje-McKenna, unpublished results) as a template using the 
SWISS-MODEL model building program.38 The first 217 N-terminal resi-
dues of AAV-1 are disordered in the crystal structure and thus this region 
could not be modeled in AAV-6. The three-dimensional models for HAE-1, 
and HAE-2 were then created by “cutting and pasting” the structural 
regions from the parental virus followed by regularization of the model 
geometry in the program Coot.39 Due to the structural localization of the 
amino acids that differ between AAV-1 and AAV-6 in a VP3 monomer 
around the icosahedral threefold axes, a trimer was generated for each chi-
meric HAE virus model by matrix multiplication for further visualization 
of the amino acid contributions from each parental serotype. The position 
of these amino acids (five in the ordered VP3 region) were then colored 
(black for AAV-1, yellow for AAV-6) on a surface contour representation 
of the chimeric virus models using the program PyMol.40
Construction of the chimeric plasmid library and selection on HAE. The 
construction of the chimeric AAV library by capsid DNA shuffling of eight 
natural AAV serotypes, i.e., serotypes 1–9 except 7, has been previously 
2076 www.moleculartherapy.org  vol. 17 no. 12 dec. 2009 
© The American Society of Gene & Cell Therapy
Directed Evolution of Novel Adeno-associated Virus
described.10 To select for AAV variants with enhanced tropism toward 
airway epithelium, the AAV library was screened with well-ciliated HAE 
cultures, illustrated in Figure 1a. Briefly, 100 μl of the AAV library (MOI 
of 1,000) were inoculated onto the apical surface of four 24-mm HAE 
 cultures, incubated for 4 hours at 37 °C before removal of the library and 
washing of the apical surface of HAE cultures three times with phosphate 
buffered saline. At 24 hours after AAV inoculation, the HAE cultures were 
infected with wild-type AdV dl309 (MOI of 20) on treatment with sodium 
caprate.17 AAV virus particles were harvested at 4 days after AdV infec-
tion by lysing the cells with repeated freezing and thawing, followed by 
heat inactivation of wild-type Adv. The harvested AAV pool was then used 
for the next round of screening as carried out in the first round, and so 
on. At the end of each round of screening, viral genomic DNA was puri-
fied from 50 μl aliquots of crude cell lysates using the DNeasy kit (Qiagen, 
Germantown, MD) for the determination of viral genome titer by dot-
blot hybridization. After five successive rounds of screening, individual 
AAV clones were picked and subjected for DNA sequencing analysis. 
Representative AAV variants were cloned into the pXR2 backbone and 
used as AAV helper plasmids to produce recombinant AAV viruses.
Apical transduction of HAE with recombinant AAV vectors. CF and 
non-CF HAE cultures were inoculated on the apical surface with 100 μl 
of AAV vectors for 2 hours. The MOI varied from 1 × 103 to 4 × 105 vec-
tor genomes/cell, depending on virus concentration and purposes of the 
experiments. Equal MOI was used within each experiment. The protea-
some-modulating agent, LLnL (40 μmol/l), or the chemotherapeutic anthra-
cycline, Dox (5 μmol/l),19,34 were applied when noted. Photomicrographs of 
transduced GFP-positive cells were acquired using a Leica Leitz DMIRB 
inverted fluorescence microscope equipped with a cooled-color charge-
coupled device digital camera (Retiga 1300; Q-Imaging, Burnaby, British 
Columbia, Canada). Images of five random fields for each HAE culture 
were captured and quantified using ImageJ software (National Institutes 
of Health, Bethesda, MD). To identify AAV transduced cell types, ciliated 
cells were immunolabeled with a β-tubulin IV antibody (Sigma-Aldrich, 
St Louis, MO), followed by AlexaFluor594 conjugated goat anti-mouse 
antibody (Invitrogen, Carlsbad, CA) as described previously.41 Optical x-z 
fluorescent confocal images were obtained using a Zeiss 510 Meta Laser 
Scanning Confocal Microscope (Carl Zeiss Micro Imaging, Thornwood, 
NY). In HAE inoculated with luciferase expressing AAV vectors, luciferase 
activities were measured using a luminometer (Victor2 1420 Multilabel 
Counter; Perkin Elmer Life Sciences, Canton, MA).
Western-blot analyses of CFTR expression. HAE/293T/HeLa cells were 
lysed in M-PER buffer (Pierce, Waltham, MA), and equal amounts of total 
protein were separated with a NuPAGE 3–8% Tris–Acetate Gel (Invitrogen, 
Carlsbad, CA) and transferred to polyvinylidene difluoride membranes. 
The membranes were then probed with a CFTR-specific antibody (#596, a 
gift of Dr Jack Riordan) followed by HRP conjugated goat anti-mouse anti-
body (Jackson ImmunoResearch, West Grove, PA); and CFTR visualized 
with SuperSignal West Dura Substrate (Pierce, Waltham, MA).
Ion transport measurements. HAE were mounted in Ussing chambers for 
measurement of transepithelial resistance and transepithelial potential dif-
ference. The cultures were studied under open circuit conditions using a volt-
age clamp (Physiologic Instruments, San Diego, CA). The electrical potential 
difference across the tissue was continually recorded and a constant current 
pulse (2–10 μA) applied across the tissue at 1-minute intervals to calculate 
tissue resistance. From these measurements, the equivalent short-circuit 
current (Isc) was calculated. All other details of Ussing chamber techniques 
have been previously published.42 HAE were bathed in Krebs bicarbonate 
ringer solution on the serosal side, and high K+ low Cl− (HKLC) buffer on 
the lumenal side. Both solutions were gassed with 95% O2, 5% CO2. Drugs 
[amiloride (10−4 mol/l), forskolin (10−5 mol/l), and CFTR172 (10
–5 mol/l)] were 
added from concentrated stock solutions to either lumenal and/or serosal 
surfaces (all obtained from Sigma-Aldrich). CFTR functional activities (for-
skolin ΔIsc) were measured in AAV  inoculated CF HAE at 14 days p.i.
Statistics. All data are expressed as means ± SEM. Unpaired Student’s t-test 
was used to assess the difference between groups. P value of <0.05 was 
considered significant.
suPPleMentAry MAterIAl
Figure S1. The binding of AAV to the apical surface of HAE is not sig-
nificantly different among HAE-1, HAE-2, AAV-1, and AAV-6.
Figure S2. Histological analysis of HAE at 2 and 4 weeks post ALI.
Figure S3. AAV transduction was more efficient in nondifferentiated 
than fully differentiated HAE.
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